Back to News
Market Impact: 0.12
Lōkahi Therapeutics™ Continues ai² Pipeline™ Division Collaboration with The University of Alabama to Advance Asset Evaluation and Biopharma Talent
Source: Business Wire
Healthcare & BiotechPrivate Markets & Venture
Lōkahi Therapeutics renewed its collaboration with the University of Alabama to advance real-world asset evaluation and support development of future biopharma talent. The announcement signals continued investment in research capabilities and workforce development, but provides no financial terms, clinical data, or near-term commercial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.22
More News
- Flock Offers Employees Buyouts as Customers Flee
- Anthropic’s Claude Takes Bigger Role in Building AI
- ProEnergy eyes $40 billion to $50 billion valuation in US IPO
- Anthropic delays IPO staging to November amid AI fears, WSJ says
- Anthropic quietly sets up biology lab as it ramps AI drug program: Reuters
- Activist Jana Pushes Cooper Cos. to Replace CEO, Board Chair
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Eli Lilly Q4 2025 Earnings: Revenue Surges 43% as Mounjaro and Zepbound Dominate the GLP-1 Market
- Investment Research Software Costs: A 2026 Budget Framework